… ProQR Announces Conference Call to Discuss the Axiomer® RNA Editing Platform LEIDEN, Netherlands & … conference call and webcast to discuss the Company’s Axiomer RNA editing technology platform following the …
… Research Collaboration on Fibrosis Targets Using ProQR’s Axiomer® technology LEIDEN, the Netherlands, Jan. 08, 2018 … collaboration we will explore a novel application of our Axiomer® technology to Galapagos’ fibrosis targets,” said …
… R&D day Highlights Progress on Pipeline and Introduces Axiomer®, a novel proprietary RNA Technology Key program … the unmet need in DEB and the current treatment landscape. Axiomer®: ProQR will introduce its novel, proprietary RNA …
… ProQR Announces Conference Presentations for Axiomer® RNA Editing Technology and QR-313 for DEB LEIDEN, … 2018 Conference ProQR will deliver a presentation on the Axiomer ® RNA editing technology during the TIDES: …
… ProQR Presents in vivo Proof of Concept Data for the Axiomer® RNA Editing Platform Technology Key updates ProQR … (Nasdaq:PRQR), today announced that a presentation titled “Axiomer ® Technology: Therapeutic Oligonucleotides for …
… Dr. Peter A. Beal to Scientific Advisory Board to Focus on Axiomer® RNA A-to-I Editing Technology Key Updates Dr. Peter … in advancing the company’s novel and proprietary Axiomer ® RNA editing technology. The board now consists of …
… focuses on developing potential medicines using our Axiomer RNA editing platform technology. Strategic … drive the advancement of an early-stage technology, like Axiomer, closer to the clinic. Today we are delighted to … announced in September 2021 , applied ProQR’s proprietary Axiomer™ RNA editing platform to target disorders of the …
… the event, the Company will showcase its proprietary Axiomer ® RNA-editing technology platform, announce initial … and mentored over 50 Ph.D. and M.S. degree students. About Axiomer ® ProQR is pioneering a next-generation RNA base editing technology called Axiomer ® , which could potentially yield a new class of …
Bart Klein was at the forefront of ProQR's Axiomer® RNA editing technology development. This platform technology makes it possible to use the cells own machinery to reverse mutations that cause a genetic disease. Read the interview.
